Publications by authors named "Patrick Engelberts"

Claim this Profile
C
CD3xHER2 bsAb-Mediated Activation of Resting T-cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα.
Chen-Yi Liao, Patrick Engelberts, Michiel van Dijk, Annemieke Timmermans, John W M Martens

Eur J Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing.
Chen-Yi Liao, Patrick Engelberts, Andreea Ioan-Facsinay, Janna Eleonora Klip, Thomas Schmidt

Commun Biol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Kristel Kemper, Ellis Gielen, Peter Boross, Mischa Houtkamp, Theo S Plantinga, Patrick J Engelberts

Life Sci Alliance· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F Labrijn, Janine Schuurman

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Patrick J Engelberts, Ida H Hiemstra, Bart de Jong, Danita H Schuurhuis, Joyce Meesters

EBioMedicine· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".
Patrick J Engelberts, Esther C W Breij, T Valerius, J Schuurman, Paul W H I Parren

J Immunol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Patrick J Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M Bakker

J Immunol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.
Ewald T J van den Bremer, Frank J Beurskens, Marleen Voorhorst, Patrick J Engelberts, Rob N de Jong

MAbs· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.
Rob N de Jong, Frank J Beurskens, Sandra Verploegen, Kristin Strumane, Muriel D van Kampen, Patrick J Engelberts

PLoS Biol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Fabio Da Roit, Patrick J Engelberts, Ronald P Taylor, Esther C W Breij, Giuseppe Gritti

Haematologica· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab.
Patrick J Engelberts, Carole Badoil, Frank J Beurskens, Danièle Boulay-Moine, Karine Grivel

J Immunol Methods· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Frank J Beurskens, Margaret A Lindorfer, Mohammed Farooqui, Paul V Beum, Patrick Engelberts

J Immunol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Paul V Beum, Elizabeth M Peek, Margaret A Lindorfer, Frank J Beurskens, Patrick J Engelberts

J Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.
Frank J Beurskens, Sigrid R Ruuls, Patrick J Engelberts, Tom Vink, Wendy J Mackus

Blood· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
Magdalena Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz M Wilczynski, Malgorzata Lekka, Patrick J Engelberts

PLoS Med· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of the pap epigenetic switch by CpxAR: phosphorylated CpxR inhibits transition to the phase ON state by competition with Lrp.
Aaron D Hernday, Bruce A Braaten, Gina Broitman-Maduro, Patrick Engelberts, David A Low

Mol Cell· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis